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Abstract
Serpins build a large and evolutionary widespread protein
superfamily, hosting members that are mainly Ser-protease
inhibitors. Typically, serpins display a conserved core domain
composed of three main b-sheets and 9–10 a-helices, for a
total of approximately 350 amino acids. Neuroserpin (NS) is
mostly expressed in neurons and in the central and peripheral
nervous systems, where it targets tissue-type plasminogen
activator. NS activity is relevant for axogenesis, synaptoge-
nesis and synaptic plasticity. Five (single amino acid) NS
mutations are associated with severe neurodegenerative dis-
ease in man, leading to early onset dementia, epilepsy and
neuronal death. The functional aspects of NS protease inhi-
bition are linked to the presence of a long exposed loop
(reactive center loop, RCL) that acts as bait for the incoming
partner protease. Large NS conformational changes, associ-
ated with the cleavage of the RCL, trap the protease in an
acyl-enzyme complex. Contrary to other serpins, this com-
plex has a half-life of approximately 10 min. Conformational
flexibility is held to be at the bases of NS polymerization
leading to Collins bodies intracellular deposition and neu-
ronal damage in the pathological NS variants. Two main gen-
eral mechanisms of serpin polymerization are currently
discussed. Both models require the swapping of the RCL
among neighboring serpin molecules. Specific differences in
the size of swapped regions, as well as differences in the
folding stage at which polymerization can occur, distinguish
the two models. The results provided by recent crystallo-
graphic and biophysical studies allow rationalization of the
functional and pathological roles played by NS based on the
analysis of four three-dimensional structures.
Keywords: a1-antitrypsin; crystal structure; dementia;
familial encephalopathy with NS inclusion bodies
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Neuroserpin and the serpin superfamily
Neuroserpin (NS) is a 55-kDa secretory protein mainly
expressed in neurons of the central and peripheral nervous
systems (1); from the neuron it is secreted in a function-
related manner, after being stored in regulated secretory
granules (2). NS seems to have various physiological and
physiopathological functions. It participates in axonogenesis
and synaptogenesis during development, and it contributes
to synaptic plasticity in the adult (3). NS is also involved in
the regulation of permeability between the vascular and nerv-
ous system compartments, where, under pathological con-
ditions such as cerebral ischemia, seizures and stroke, it has
been shown to play a protective role, preventing neuronal
cell death (4–6). NS exerts its recognized roles mainly as an
inhibitor of tissue-type plasminogen activator (tPA). NS
mutants are responsible for a severe neurodegenerative dis-
ease leading to neuronal death and dementia, known as
familial encephalopathy with NS inclusion bodies (FENIB)
(7). Finally, NS has been found to interact with the b-amy-
loid (Ab) peptide in Alzheimer’s disease (8).
NS belongs to the serpin (serine protease inhibitor) family,
thus sharing the general fold, structural properties and mech-
anism of action of several known family members; indeed,
the serpin superfamily comprises proteins from every kind
of organisms, from archaea to man (9, 10). Most serpins act
as serine-protease inhibitors; generally, each serpin recogniz-
es a target protease, which is specifically and efficiently
inhibited. However, members of the family have been iden-
tified as cysteine proteinase inhibitors (11). In addition, there
are few but notable exceptions: some selected serpins per-
form other roles, such as hormone transport, protein folding
and chromatin condensation (12–14).
Despite displaying a low sequence conservation within the
whole family (below 25%), serpins share a core domain of
similar size (;350 residues) and, in particular, all three-
dimensional structures available to date show that the serpin
fold is well conserved through the phyla (15, 16). Such a
fold consists of a domain characterized by three b-sheets
(named A, B and C), eight or nine a-helices (named A to
H/I) and a 20-residue exposed loop, known as the reactive
center loop (RCL) (17) (Figure 1). The main b-sheet, sheet
A, is composed of five or six b-strands depending on the
serpin conformation (explained below): the A-sheet is mainly
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Figure 1 Sketch representation of (A) native and (B) cleaved hNS.
The A-, B- and C-sheets are colored red, blue and yellow, respectively; the helices are green and coil regions including the RCL are colored
gray (see also Figure 3). b-Strands and a-helices are labeled according to the standard serpin nomenclature.
solvent exposed and it is a major player in the mechanism
through which serpins exploit their function. The antiparallel
six-stranded B-sheet is almost completely buried in the ser-
pin fold, sandwiched between the A-sheet and helices hA,
hG and hH. The C-sheet is on the apex of the serpin fold, it
is solvent exposed and it is contiguous to the RCL. As
explained below, this sheet consists of three or four strands,
in the native or the cleaved forms, whereas in the latent
conformation the first b-strand of the C-sheet (s1C) becomes
unfolded (18).
To inhibit their target protease serpins exploit a unique
mechanism: the RCL is specifically recognized by the target
protease, which cleaves it triggering a fascinating structural
rearrangement. Such conformational change results in the
insertion of the cleaved RCL in the A-sheet as strand 4 (s4A)
(Figure 2). In cases of protease inhibition, the protease
remains acylated and thus covalently bound to the RCL.
Conversely, when the serpin acts as a substrate, the RCL is
cleaved and inserted as s4A, but the acyl-enzyme complex
is promptly hydrolyzed. Such conformational change is ener-
getically driven owing to a transition from a ‘stressed’ (S)
to ‘relaxed’ (R) serpin conformation. Indeed, the higher sta-
bility of the cleaved relaxed conformation versus the stressed
native conformation has been well established (17, 19). In
fact, unlike most globular proteins, serpins spontaneously
fold to a metastable native conformation (20). Although the
serpin folding mechanism is yet to be completely uncovered,
it has been observed that serpins always fold to the native
metastable but physiologically active conformation, which is
a local minimum, and do not reach the most stable confor-
mations (latent and polymer, described below).
The metastability of native state renders serpins extremely
susceptible of misfolding and prone to transition to non-func-
tional conformations. In fact, native (uncleaved) serpins can
assume a second conformation known as ‘latent’, which is
characterized by the insertion of the RCL in the A-sheet in
the absence of a proteolytic cleavage (21). As a consequence
of the insertion of the RCL, the first strand of the three-
stranded C-sheet (s1C) is unfolded and converted to a coil
(18). The serpin latent form very closely resembles the RCL-
cleaved form in several ways: (i) structurally, both forms
have the RCL inserted into the A-sheet; (ii) functionally, both
are inactive as protease inhibitors; and (iii) thermodynami-
cally, both have similar fold stability (17). In a few cases the
latent form has been proven to act as a serpin reservoir,
which upon ligand binding can readily revert to native and
inhibit the target protease (22).
In addition to the latent form, both in vitro and in vivo,
serpins can also aggregate to form quasi-native elongated
polymers that can be depicted in electron microscopy images
as beads-on-a-string filaments (17, 23). Although the molec-
ular details of serpin monomeric forms are well characterized
owing to several crystal structures, different models of serpin
polymerization that are rooted in structural modifications of
the A-sheet or of the C-sheet, have been proposed, and are
still openly debated (24–28).
In the present review, the physiological and pathological
roles of human NS will be examined in the frame of the
wider knowledge acquired on the entire serpin superfamily.
First, the NS gene expression and cellular localization will
be reviewed. Then, the somewhat unclear NS role in brain
development and pathology will be analyzed together with
its peculiar inhibitory properties. Human NS (hNS) point
mutations are at the base of FENIB, an autosomal dominant
dementia, and the effects of such pathological point muta-
tions on hNS function, fold and aggregation state will be
evaluated. Finally, structural and biophysical data on hNS
will be reviewed. Despite a substantial ongoing scientific
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Figure 2 (A–C) Sketch representation of the three steps of serpin-protease complex formation, leading to protease inhibition.
The serpin molecule is shown in green, the protease in blue; the RCL is colored magenta. (A) A serpin molecule and a serine protease are
shown separately; (B) the Michaelis complex, where the RCL interacts tightly with the protease active site; and (C) once the RCL is
cleaved, it is inserted in the A-sheet and the protease is dragged on the opposite side of the serpin molecule. To produce the Figure the
following pdb codes were used: (i) 1OPH and 3F5N, (ii) 1OPH, and (iii) 1EZX. (D) SDS-PAGE shows the reaction between tPA and hNS
over time (from 0 to 180 min): the bands corresponding to native and cleaved hNS as well as the covalent NS-tPA complex (cpx) are
visible. Adapted, with permission, from Elsevier Ltd., J Mol Biol (2009; 388: 109–21),  (2009).
effort to reveal the intriguing cellular and molecular aspects
of hNS function in healthy individuals and in disease, a full
picture is far from being depicted. The present review will
show that NS can be considered a most interesting member
of the serpin superfamily, both for its role in human health
and as a molecular model for serpin physiological and path-
ological processes.
Neuroserpin: from gene to secretion
The very first evidence for the existence of NS (originally
called axonin-2, because its most prominent feature was its
axonal secretion) dates to the late 1980s, when it was iden-
tified as a protein secreted by cultured chicken dorsal-root-
ganglia neurons (29). Subsequently, when its cDNA was
cloned and the deduced amino acid sequence qualified the
protein as a novel member of the serpin family, it was named
neuroserpin (30). One year later, hNS cDNA was identified
from a fetal retina cDNA library (31), with the Human Gene
Mapping Workshop (HGMW)-approved symbol PI12 (pro-
tease inhibitor 12). In 2001, Silverman et al. revised the ser-
pin nomenclature classifying it as SERPINI1 (10). Mouse
and rat NS cDNAs have also been cloned (32, 33). Either
cloned or predicted, NS cDNA has been recognized from
mammals to non-mammalian vertebrates (http://www.ncbi.
nlm.nih.gov/homologene), with a high level of sequence
identity in mammals (from 85% to 99%), where the cDNA
encodes a 410-residue protein. It soon appeared evident that
NS is mainly secreted from neurons of the central and
peripheral nervous systems (1). Later NS was also detected
in cells of the myeloid lineage (34) and of endocrine tissues
(32, 35, 36), where it is stored in regulated secretory granules
(2).
The molecular mass of the mature protein is ;55 kDa, as
seen in SDS-PAGE (1, 3, 7, 30, 32, 37), in accordance with
the presence of potential N-glycosylation sites (three in
mammalian NS, located at Asn157, Asn321 and Asn401;
two in chicken NS, where residue 321 is Asp) (37) (Figure
3); nevertheless, the actual glycosylation pattern has never
been analyzed in depth. With some exceptions (1, 38, 39),
the majority of biochemical studies on NS have been per-
formed with a protein expressed in Escherichia coli, thus
lacking glycosylation. It should be recalled that all available
evidence indicates that basic serpin inhibitory mechanism
does not depend on NS glycosylation. Recently, a eukaryotic
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Figure 3 Sequence alignments of human neuroserpin (hNS), plasminogen activator inhibitor-1 (PAI-1), a1-antitrypsin (a1-AT) and tengpin
(tngpn) from the extremophile Thermoanaerobacter tengcongensis. Sequence numbering is based on hNS (15). The following residues are
highlighted: N- and C-terminal peptides are marked with a two-headed arrow above the sequence; the ‘omega loop’ (from Gly231 to Ala237)
is highlighted by a black X; the putative N-glycosylation sites (Gln157, Gln321, Gln401) by black arrows; residues 161–163 (NLV) by a
black ; residues whose mutation cause FENIB (Ser49, Ser52, His338, Arg392) by red stars. ‘h’ and ‘s’ represent helices and strands,
respectively. The A-, B- and C-sheets are colored red, blue and yellow, respectively; the helices are green and coil regions including the
RCL are colored gray (secondary structures are color-coded as in Figure 1).
high-level expression system in Drosophila melanogaster
has been developed (40).
Some doubts remain on the primary structure of hNS con-
cerning the length of the N-terminal signal peptide: both
from ex vivo and cell culture experiments, hNS seems to
present a heterogeneous N-terminus, with the majority of the
molecules starting at Thr20, and the rest at Ala19 (37, 40,
41) (Figure 3). The chicken, rat and mouse proteins, instead,
present a more obvious signal sequence of 16 residues.
At the other end of the protein molecule, NS C-terminus
is peculiar among serpins, because a novel C-terminal 13-
amino acids sorting signal has been identified that is both
necessary and sufficient to target NS to the regulated secre-
tion pathway (2) (Figure 3). Unlike NS, most serpins are
either constitutively secreted or localized to the cytoplasm
(42). NS, pancpin (a pancreas specific serpin) and the ER-
localized serpins are exceptions in this general pattern, and
both NS and the ER-localized serpins appear to contain their
targeting sequences at their C-termini. The results on the
only available crystal structures comprising the 10 residues
at the C-terminus (43) confirmed that this loop is extremely
flexible and exposed to the solvent, potentially allowing
interaction with other ligands. The levels of secreted NS
could thus be regulated post-translationally. As detailed
below, NS levels are also regulated transcriptionally and
post-transcriptionally, indicating that NS activity is finely
tuned.
By fluorescence in situ hybridization the hNS gene was
mapped to region q26.1 of chromosome 3 (31). It spans
1907 bp and includes nine exons. Cell culture studies indi-
cated that its transcription is enhanced by neuronal depolar-
ization (44), and it is post-transcriptionally regulated by
thyroid hormone (T3), through a stabilizing effect on mRNA
(45); the T3 effect was also verified in a mouse model. A
regulation of NS expression both at the transcriptional and
translational level was confirmed in a physiological contest
in Xenopus laevis (46).
An unusual feature of the NS gene is that it is closely
adjacent in a head-to-head configuration to a non-homolo-
gous gene, the PDCD10 programmed cell death gene (47).
These two genes are separated by an exceptionally short
intergenic region of 851 bp that tightly links them together
through an asymmetric bidirectional promoter of 175 bp. In
cooperation with other cis-acting elements, this promoter is
responsible for the coregulation of the genes expression pat-
tern as well as their tissue specificity, being essential for
transcriptional activation of both genes. The oncogenic
c-Myc transcription factor was identified to drive the expres-
sion of the two genes, suggesting that it plays an important
role in regulating their coordinated transcription, and it is
possibly involved in their differential expressions in central
nervous system diseases such as brain cancer (48). Finally,
the structure of the PDCD10-SERPINI1 bidirectional gene
pair is conserved in mammals, indicating an evolutionary
requirement to maintain their cotranscriptional status and
functional association (47).
Physiological and pathophysiological function
of neuroserpin
Although all physiological functions of NS are not complete-
ly understood, it is recognized that NS participates in axo-
nogenesis and synaptogenesis during development, while it
contributes to synaptic plasticity (learning and memory) and
control of emotional behavior in the adult (3). The main
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evidence supporting NS involvement in these processes
include: (i) its spatial and temporal expression in tissue con-
cerned with neural plasticity (3, 30), together with the obser-
vation of an activity-regulated transcription, meeting a
criterion generally associated to ‘plasticity-related’ proteins
(44, 46, 49–51); (ii) impaired explorative behavior and neo-
phobia in mice lacking or overexpressing the protein (52);
(iii) cell culture studies showing that NS regulates processes
such as neurite outgrowth (32, 36); (iv) and finally the fact
that it is generally accepted that NS exerts its recognized
physiological role mainly as an inhibitor of tPA; indeed, the
involvement of tPA in synaptic plasticity is well proven (53),
although a tPA-independent action has also been demon-
strated (52, 54).
The indication that tPA is the target protease inhibited by
NS comes primarily from spatiotemporal tissue distribution
analysis, that demonstrates that expression of tPA and NS in
the central nervous system (CNS) overlaps (55, 56), pointing
to NS as the natural counterbalance to tPA, during both nor-
mal brain function and disease. In vitro enzyme assays
revealed that NS inhibits tPA, and only to a lesser extent
urokinase-type plasminogen activator and plasmin (1, 3, 38,
43), although the NS-target protease complex has not thus
far been characterized in vivo.
The mechanism that regulates NS/tPA balance is now
emerging via the characterization of the regulation of NS
secretion. As detailed above, new findings indicate that NS
is targeted to a regulated secretory pathway in neurons via a
novel C-terminal sorting sequence (2). Ishigami et al. (2)
suggest that the mobilization and secretion of NS from a
reserve pool could be mediated by retrograde signaling from
a synaptic site that is triggered in response to increased levels
of tPA activity at the synapse. Alternatively, tPA and NS
could be extensively copackaged in dense core granules (57).
NS could thus act as inhibitor of the residual tPA activity
intracellulary. In favor of this hypothesis, a recent study by
Belorgey et al. (58) has shown that NS is stabilized at low
pH and maintains its inhibitory activity, in accordance with
the acidic environment (pH 5–6) of the storage vesicles.
NS and NS-tPA complex cell internalization and degra-
dation is mediated by the low-density lipoprotein receptor-
related protein (LRP) on the cell surface (59); in fact, LRP
is the principal clearance receptor for serpins and serpin-
proteinase complexes.
The role of NS has also been proven under CNS patho-
logical conditions. tPA has different functions in the CNS
(53); other than its physiological participation in synaptic
plasticity, it is also involved in the regulation of permeability
between the vascular and nervous system compartments. An
unbalanced tPA activity could thus be the cause of patholog-
ical outcomes, such as cerebral ischemia, seizures and stroke.
In these situations, NS has been shown to play a neuropro-
tective role, slowing the progression of injury throughout the
CNS and preventing neuronal cell death (4–6). Moreover,
NS is thought to participate in disparate pathological states
such as motoneuron degeneration and brain cancer (48, 60,
61).
Point mutations of NS are responsible for FENIB, a severe
neurodegenerative disease leading to neuronal death and
dementia (Figure 5). FENIB is an autosomal dominantly
inherited disease, characterized clinically as a spectrum of
phenotypes, from dementia to epilepsy with variable electri-
cal status (23). Histologically, FENIB is associated with
unique neuronal inclusion bodies distributed throughout the
cerebral hemispheres, but is significantly more abundant in
the cortex and in the substantia nigra (7). At the biochemical
level NS polymers are a hallmark of the disease (62). The
NS inclusion bodies, known as Collins bodies, after Dr.
George H. Collins, who initiated the first study on FENIB,
are distinctly different from any other protein form previ-
ously linked to neurodegeneration (7). NS polymers are
based on an entanglement of ordered polymeric chains that
display a morphology identical to the polymers (intracellu-
larly) formed by other serpins (41). For this reason, FENIB
is included among the diseases imputable to serpin poly-
merization, collectively known as serpinopathies (63).
To date, five hNS mutations (each in a single family,
except for the S52R mutation that has been found in two
unrelated families) have been found associated with FENIB:
S49P, S52R, H338R, G392E and G392R (64, 65) (Figure 4).
Evidence has been accumulated that shows a direct corre-
lation between severity of disease, amount of intraneuronal
NS inclusions and predicted degree of conformational insta-
bility of the NS mutants, according to the following order of
severity/protein instability: G392E/R)H338R)S52R)S49P
(23). The main phenotypical and biochemical features of
FENIB deduced, respectively, from its clinical manifestations
and from the postmortem analysis of affected brains were
confirmed through the expression of mutants in mice (52,
66), in Drosophila melanogaster (62) and in diverse cellular
systems (62, 67). The animal models confirmed the clinical
phenotype, whereas the cellular systems were essential to
disclose the molecular details of intracellular protein accu-
mulation. As seen from ex vivo studies, NS mutants accu-
mulate as polymers within the endoplasmic reticulum (ER)
(67), given that the quasi-folded nature of the component
moieties fails to activate the unfolded protein response
(UPR) (68). In contrast, the accumulation of polymers acti-
vates a UPR-independent ER-to-nucleus signal transduction
pathway that has been called the ordered protein response,
mediated by the activation of the transcription factor NF-kB.
Because this pathway might regulate key processes induced
during cellular stress, it could contribute to the cell death
that is triggered by the accumulation of hNS polymers lead-
ing to dementia (69). Such studies point out that intracellular
polymerization could be an important source of neurodege-
neration, but do not exclude that the loss of hNS inhibitory
activity due to mutations, with the consequent increase of
active tPA concentration at the synapses, could aggravate the
neuropsychiatric and epileptic aspects of FENIB (70–72).
Mainly based on studies on a1-antitrypsin (a1-AT) poly-
merization, therapies to block polymerization and treat the
serpinopathies are under investigation (73–75). Although
some achievement has been reached, none of the proposed
remedies has yet been proven to be effective in man.
Finally, NS has been found to interact with the Ab peptide
(8, 76) with remarkable effects. First the interaction with Ab
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Figure 4 (A) Stereo sketch representation of the crystal packing in the asymmetric unit of full length hNS (pdb code 3F5N). It should be
noted that the five RCLs are at the core of the chain-to-chain interaction region. (B) Stereo representation of hNS (pdb code 3FGQ): the
omega loop is highlighted as cyan spheres (residues 231–237), residues 161–163 are shown as magenta sticks, and the region s1A-hE is
in blue.
decreases the NS protease inhibitory activity, and second it
promotes Ab amyloid aggregation (8). The same study
revealed that in cell lines and in a Drosophila model, NS
exerts a protective role against the toxicity of Ab peptide
aggregates. Furthermore, it has been proven that NS is upre-
gulated in brain of patients affected by Alzheimer’s disease
(77), and higher cerebrospinal fluid levels of NS in Alzhei-
mer’s patients were associated with the clinical diagnosis of
the disease, facilitating its diagnostic classification (78).
Notably, another serpin, a1-antichymotrypsin, is always
found associated with Ab plaques in Alzheimer’s patients
(79). The role of a1-antichymotrypsin, however, is contro-
versial because it has been proposed to either inhibit (80) or
accelerate amyloid aggregation (81). The latter studies, sup-
porting an a1-antichymotrypsin role in fibrillogenesis accel-
eration, indicate a specific role for accessory proteins in the
formation of amyloid deposits.
Inhibitory properties of neuroserpin in relation
to general serpinology
Serpins are slow-binding inhibitors (82); the molecular
mechanism they exploit to inhibit serine proteases has been
established in fascinating detail. In the serpin active confor-
mation, the RCL is a solvent exposed and flexible loop, bear-
ing the P1 residue (Figures 1 and 3), a recognition site for
the target protease, which usually binds the serpin with very
high affinity. Thus, first the protease binds to the serpin
forming a non-covalent Michaelis-like complex mainly
through recognition of the RCL (83, 84). Then, the protease
cleaves the RCL at the P1-P19 bond by a conventional Ser-
protease nucleophilic attack on the carbonyl C of the scissile
peptide bond. Such cleavage triggers a profound conforma-
tional change, which is the beauty and the Achilles’ heel of
the serpin molecule. Upon cleavage the RCL moves from its
exposed site to a location nestled within the A-sheet, as s4A
(Figure 2). The A-sheet, thus, opens up to accommodate the
additional b-strand. The region of A-sheet which moves to
make room for the RCL is known as the shutter region and
mainly consists of strands s3A, s5A and the neighboring sec-
ondary structures (s1A, s2A, s3A, hF) (17). Such dramatic
conformational changes occur before hydrolysis of the acyl-
enzyme complex, and therefore the protease is dragged by
the RCL for approximately 70 A˚ , from one side to the oppo-
site of the serpin structure (Figure 2). Crystal structures have
elegantly shown that the protease active site is inactivated
by stereochemical deformation, preventing hydrolysis of the
complex, which is generally stable for weeks (85, 86). Two
X-ray structures of serpin/protease complexes available to
date show a distorted protease active site, but the protease
moieties appear differently affected and significantly rotated
relative to one another. Thus, the extent of the serpin-induced
protease distortion, although substantial, remains unclear and
could well vary in different serpin-protease complexes. The
serpin conformational changes triggered by the protease
cleavage are thermodynamically driven; the cleaved species
where the RCL is inserted in the A-sheet is energetically
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much more stable than the native (uncleaved) form, which
in turn is considered a metastable conformation (19, 87, 88).
The P1-P19 bond in hNS links residues R362–M363 (Fig-
ure 3). The P1 residue is the primary determinant of serpin
specificity for the target protease; not surprisingly, the P1
specific residue for tPA is an arginine. Nevertheless, the
kinetic behavior of hNS clearly differs from the virtually
irreversible inhibitory processes paradigmatically related to
other serpins. Despite a relatively efficient rate of inhibition,
corresponding to a second order rate constant of the order of
105 M-1s-1, in vitro the hNS/tPA complex is short-lived (with
a half-life of 10 min) (Figure 2), more reminiscent of a
delayed intermediate of a substrate hydrolysis process (39,
43, 70). An immediate physiological consequence is that rec-
ognition of the NS-tPA complex by receptors must occur in
a matter of minutes for cellular internalization to take place.
No direct evidence of the hNS-tPA complex has been thus
far reported in vivo, although cellular internalization, a pro-
cess mediated by LRP receptor recognition, has been
observed in cell cultures, both for active hNS and for the
hNS-tPA complex (59). It should, however, be mentioned
that an undefined complex of the size of hNS-tPA has been
identified in murine brain extract (1). To date, no cofactors
have been found to bind hNS or tPA in a physiological envi-
ronment that could stabilize the complex (39).
From a structural point of view, transient inhibition of tPA
by hNS, resulting in cleaved NS, implies that the deforma-
tion of the protease active site in the hNS-tPA complex is
not sufficient to prevent the deacylation reaction (85, 86).
Calugaru et al. have shown that the inactive protease con-
formation (in the serpin-protease complex) is in a dynamic
equilibrium with active conformation that can complete the
catalytic cycle and thereby slowly release a cleaved serpin
and its protease partner (89). The equilibrium can be shifted
by the preferential binding of protease ligands to one of the
two conformations. To date, such a ligand has not been found
for the NS-tPA pair.
Recent reports have shown that stable serpin/acyl-enzyme
complexes require full insertion of the RCL in the A-sheet
(42, 90), thus short-lived complexes might be generated by
improper RCL length (91). As in NS the cleaved RCL, after
release of the protease, adopts a conformation (as s4A) sim-
ilar to other cleaved serpins (43) (Figure 1), the length of
the RCL is unlikely to be responsible for the faster turnover
of the NS-tPA complex. RCL full insertion could also be
prevented by competing interactions between the serpin and
the protease (92). The high affinity displayed by serpins for
cognate proteases is modulated by exosites present on the
interacting surfaces of both macromolecules (93). A well-
known example is the inhibition of tPA by plasminogen acti-
vator inhibitor-1 (PAI-1). The tPA variable region-1 (VR-1
or 37-loop) is an exposed loop rich in positively charged
residues, mapping near one edge of tPA active site, which is
crucial for enhancing the rate of inhibition of tPA by PAI-1.
The region of PAI-1 interacting with tPA VR-1 has been
identified as the negatively charged residues in the RCL
region C-terminal to the cleavage site (proximal hinge) (94,
95). Differently from PAI-1, NS does not exhibit charged
residues at the proximal hinge; instead, a peculiar negatively
charged patch is present on one side of the A-sheet, which,
on the contrary, is absent in PAI-1. Because, upon cleavage,
the bound protease is translocated toward the opposite pole
of the serpin molecule, electrostatic interactions between the
positive tPA VR-1 loop and the strongly negative NS surface
might lead to a reduction in the rate of tPA translocation
(43). This would allow trapping of the NS-tPA acyl-enzyme
complex into a relative energy minimum before the RCL is
fully inserted into the A-sheet. Such an intermediate step
might affect tPA migration on the NS surface and the
achievement of protease active site deformation, leading to
hydrolysis of the complex and enzyme dissociation (92).
Neuroserpin crystal structures
To date, four NS crystal structures have been reported. The
structure of the RCL-cleaved mouse NS (mNS) was first
reported at 3.06-A˚ resolution (pdb code 1JJO) (96); more
recently, the structure of cleaved hNS has been reported at
1.85-A˚ resolution (3F02) (43) (Figure 1B). Moreover, two
native hNS structures have been published: a full length hNS
crystal structure has been reported at a resolution of 3.15 A˚
(3F5N) (43) (Figure 1B) and a hNS construct bearing a 10-
residue truncation at the C-terminus is available at 2.1 A˚
resolution (3FGQ) (97) (Figure 4B).
As expected, mNS and hNS share the common serpin fold,
consisting of three b-sheets, nine a-helices and a 20-residues
exposed RCL. Both cleaved structures clearly have their
RCL completely inserted in the A-sheet as s4A, displaying
a r.m.s.d. (root mean square deviation) of 1.1 A˚ over the
whole molecule, after structure superposition. A long stretch
of residues is not visible in the mNS crystal structure (resi-
dues 69–106, comprising a-helices hC and hD and the con-
necting loop), suggesting that either mNS has been further
cleaved by trypsin (used to cleave the RCL) or that such a
region is highly flexible (96). Conversely, in the crystal struc-
ture of cleaved hNS such a region is defined by electron
density; however, the hD helix has high B-factors and it is
isolated from the rest of the molecule by two small electron
density gaps at the N- and C-termini. In the full length hNS
native structure, the hD helix is partially or completely vis-
ible but with high B factors and solvent exposed (3F5N and
3F02) (43).
The two native hNS structures are very similar and super-
pose with a r.m.s.d. of 1.30 A˚ , calculated over 353 Ca pairs.
In both cases, the RCL is completely exposed to solvent and
it does not interact with the A-sheet, but the strands 3 and 5
of the A-sheet are tightly bound to each other. The crystal
structure of full length hNS displays five molecules per
asymmetric unit (43) (Figure 5A). An internal structural
comparison between the five hNS copies shows that the ser-
pin core is mainly rigid, whereas just a few regions of the
molecule can adopt different conformations depending on the
environment. Above all, the five RCLs show five different
conformations, where part of the RCL is often organized in
b-structure (43). The RCL conformational freedom allows
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Figure 5 (A) Stereo view of the hNS shutter region (pdb code 3F5N). The wild-type residues in positions 49, 52, 338 and 392 are shown
in magenta sticks; green sticks show the mutated residues responsible for FENIB. (B) Table showing for each of the five known hNS
mutants the tendency for polymerization, the corresponding severity of symptoms and the accumulation of Collins bodies in histological
samples. Adapted, with permission, from ANNUAL REVIEWS Inc., Annu Rev Biochem (2009; 78: 147–76).
the five molecules to be organized in a star-like arrangement
where the RCL establishes most of the intermolecular inter-
actions in the pentameric assembly. By contrast, in the C-
terminally truncated hNS structure two identical molecules
are present in the asymmetric unit (r.m.s.d. of 0.1 A˚ /374 Ca
pairs). In this case, a stretch of six residues of the RCL
adopts a conformation characterized by a left-handed a-helix
(97).
All the above observations on the two native hNS crystal
structures underline once more the extreme flexibility of the
serpin RCLs. However, additional structural elements show
evident flexibility. The loop between s1B and s2B (residues
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231–237), which protrudes from the molecule surface, is
unique among serpins (97). Such a loop is only partially
visible in the five molecules of the full length native hNS
and shows wide conformational variability. In two cases, the
electron density appears to extend the s1B strand, molecules
B and C in the crystal asymmetric unit, thus establishing b
interactions with the neighboring RCL of molecule D;
whereas, in the other cases the loop appears totally flexible
(43), as in the cleaved hNS structure (43). In the structure
of truncated native hNS (and to a lesser extent in mNS) this
region adopts an omega-loop conformation (Figure 5B),
establishing interactions with two neighboring molecules.
Notably, residues Gly231, Gly236 and Gly237 provide sub-
stantial conformational freedom that can result in high flex-
ibility and structural adaptability to interacting partners (97).
Indeed, omega loops are known to act as ligand binding site
or to regulate enzymatic activity (98). Thus, the above obser-
vations seem to suggest a role for the 231–237 loop in pro-
tein-protein interaction; in particular, it might be involved in
the interaction with tPA, as a deletion mutant lacking this
region suggests (97).
A different structural region possibly involved in protein-
protein interactions could be found in NS. Recently, two ser-
pins (PAI-1 and tengpin) have been reported to host an
allosteric site stabilizing the native versus the latent confor-
mation (22, 99); such a site would comprise the hE and hF
helices and strand s1A (residues 122–157) (Figure 5B). In
serpins, the hF C-terminal end bears a conserved consensus
sequence (GKI), which adopts a type I9 b turn conformation
(Figure 5B). hNS is an exception because this sequence is
not conserved, being substituted by NLV. The hNS triple
mutant restoring the GKI sequence (residues 161–163)
shows higher thermal stability (97). In the full length hNS
native crystal structure, such a region is involved in protein-
protein interactions that stabilize the crystal packing contacts
(43). Moreover, three residues in the crevice between hE
and s1A, shown to tune tengpin conversion from native to
the latent form, are conserved in hNS, suggesting the same
controlling role for such a region in hNS (43, 99). All the
above observations seem to suggest the presence of a site in
the area hF-s1A-hE, which can have a regulatory role in
native hNS (43, 97).
In summary, the hNS crystal structures show marked con-
formational variability in their surface regions, together with
a trend towards intermolecular interactions in three specific
regions: (i) the RCL; (ii) the loop between s1B and s2B,
which is unique for NS and could still play an undisclosed
role in the NS protein-protein network in vivo; and (iii) a
patch on a side of the A-sheet (secondary structure elements:
hF, s1A, hE) that, in analogy with other serpins, could tune
the stability of native NS (Figure 5B).
Neuroserpin mutants and polymerization
In all serpin polymer models the RCL is responsible for
bridging neighboring protein molecules to form long strings.
The s7A-insertion model has been observed in PAI-1 and
MENT, where the RCL of one molecule interacts with the
A-sheet of an adjacent molecule as the seventh b-strand
(26–28). The intermolecular interactions provided by s7A-
linkage are limited and considered transient and reversible
(26–28). The formation of C-sheet based polymers has also
been reported. As already mentioned, the s1C b-strand
unfolds upon latent formation; in such a case, the RCL inter-
acts in trans substituting s1C and bridging neighboring mol-
ecules (25, 100). In particular, both latent PAI-1 and the
latent conformation of the NS mutant (S49P) are thought to
polymerize forming C-sheet polymers (101, 102). Cleaved
serpin molecules can also be introduced in this type of poly-
mer, as previously reported (24).
However, most of the pathological polymers in vivo are
thought to be formed via the intermolecular insertion of the
RCL into A-sheet as s4A (Figure 6); therefore, this is the
type of polymer considered the most medically relevant. Two
somehow contrasting models of serpin polymers are cur-
rently available, but their correctness is still a matter of
debate. The first model, proposed by Lomas et al., suggests
that the RCL is the only structural element inserted
(swapped) into the A-sheet of an adjacent molecule during
polymerization, in analogy with what happens during the for-
mation of the latent form (where the insertion is, however,
intramolecular) (103). The iterative insertion of RCLs would
create a long string of molecules (beads-on-a-string). More
recently, Yamasaki et al. have proposed a modified model
(104). Starting from the crystal structure of a domain
swapped antithrombin dimer, they built a model in which not
only the RCL but also the neighboring b-strand s5A is inter-
molecularly swapped and inserted in the A-sheet of a neigh-
boring molecule. The two models differ not only for the
number of swapped strands. According to the one-strand
insertion model, the protein needs to be completely folded
before being able to polymerize; by contrast, for the swap
of two strands the polymerization process could start from
a serpin folding intermediate (104, 105) (Figure 6).
In analogy with what has been observed for other serpins,
the pathological mutations (promoting in vivo polymeriza-
tion) found to date for hNS lie in the shutter region: they are
S49P, S52R, H338R, G392E and G392R. Models of hNS
mutants built on the wild-type protein structure provide
explanations for their instability (Figure 4A). The S49P
mutation lies in the hinge between strand s6B and the
B-helix: as a consequence of this mutation two consecutive
prolines are placed at this hinge region, probably resulting
in a conformational strain, which affects the shutter region
as previously suggested (43). Except for the S49P mutant, in
all other cases the mutation substitutes a buried residue with
a bigger and charged one. The modeled side chains of Arg52,
Arg338, Arg392 and Glu392 all point to strands 3A and 5A,
probably affecting native hNS stability (Figure 4A). All these
mutations lead to accumulation of polymers in vivo and give
rise to the typical FENIB symptoms, with different severity
levels and onset age for the disease. As already mentioned,
the correlation between the expected mutant protein insta-
bility, the amount of Collins bodies and the severity of symp-
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Figure 6 The two models proposed for the assembly of patholog-
ical A-sheet serpin polymers. (A) The model proposed by Lomas
et al. (103) is based on the swapping of the RCL region alone (D
indicates dimer, P denotes polymer). Adapted, with permission,
from Birkha¨user Basel, Cell Mol Life Sci (2006; 63: 709–22), 
(2006). (B) The model proposed by Yamasaki et al. (104) is based
on the swapping of a more extended serpin region, comprising the
RCL and the neighboring strand s5A. Adapted, with permission,
from Macmillan Publishers Ltd., Nature (2008; 455: 1255–8), 
(2008).
toms is striking (Figure 4B). The tendency of polymerization
is reported to be S49P)S52R)H338R)G392E)G392R
(64, 65). The FENIB onset age is reported to be approxi-
mately 48, 24, 15, 13 and 8 years, for the different mutants,
respectively. The severity of the symptoms follows a similar
correlation pattern (Figure 4B).
Although no crystal structures of the known hNS mutants
are available, the S49P and S52R mutants have been bio-
physically characterized in vitro, and structural models have
been discussed (43, 70, 71, 101). The S49P mutant is shown
to be a much poorer tPA inhibitor, having a lower inhibition
constant and a higher complex dissociation rate (70). More-
over, the native S49P mutant is much more readily converted
to both latent and polymeric forms compared to wild-type
hNS. Intriguingly, in contrast with latent wild-type hNS,
latent S49P can polymerize, probably through a C-sheet
polymerization mechanism, in a similar way to what was
previously observed for the Mmalton mutant of a1-AT (24,
101). S49P hNS was extracted from Collins bodies in latent
form, short and long polymers. Thus, not only is S49P a
less efficient tPA inhibitor but it is also less stable than wild-
type hNS and readily tends to form polymers and inactive
monomers (latent) (70, 101).
The S52R mutation leads to a more severe version of
FENIB, where this mutant polymerizes more readily than the
wild-type hNS and the S49P variant (64, 71). Unexpectedly,
the thermal and chemical stabilities of the S52R mutant are
higher than those of the S49P and are very similar to those
of wild-type hNS. Moreover, tPA cleaves with very low effi-
ciency the S52R mutant, which in turn cannot be considered
neither a tPA inhibitor nor a substrate (71). All the evidence
seems to suggest that the S52R mutation leads to an aberrant
conformation where the RCL is not available for tPA cleav-
age, but at the same time it is not in the latent conformation,
given the strong tendency to polymerize. Such conformation
is reminiscent of what has been observed for the d conformer
of a1-antichymotrypsin, where the RCL is only half inserted
in the A-sheet together with the unfolded hF-helix (71, 106).
The other three hNS mutants have been studied only in
vivo. Both the severity of FENIB symptoms and the amount
of Collins bodies found in the brain suggest that the muta-
tions H338R and G392E/R lead to even more abnormal hNS
variants, more prone to form polymers and with no ability
to act as tPA inhibitors (64, 65). Recently, the behavior of
wild-type hNS and the pathological mutants have been
compared in relation to their ability to be secreted and/or to
accumulate in the ER (62). Whereas in cellular models wild-
type hNS is eventually completely secreted as a monomeric
species, S49P and S52R are secreted as monomers but are
also accumulated intracellularly and extracellularly as poly-
mers. Conversely, monomeric H338R and G392E are not
observed at all, and only polymeric hNS is present intra/
extracellularly, in particular the fraction of intracellularly
accumulated polymer is fully increased (62).
Some evidence has been gathered suggesting that the hNS
polymers are formed according to the one-strand insertion
model (Figure 6). First of all, in cell models the polymers
appear with a 30-min delay from the moment in which hNS
expression has been triggered. Although this observation
does not rule out the possibility that the polymer can be
formed from non-completely folded molecules, it shows that
it is a post-translational process (107). Moreover, kinetics of
hNS polymerization monitored by single molecule fluores-
cence seem to be better described by a kinetic scheme com-
patible with an activated molecule characterized by the
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opening of the A-sheet and partial loop insertion, therefore
according to the one-strand insertion model (76).
Conclusions and perspectives
The availability of suitable cellular and molecular investi-
gation tools is prompting the study of (severe) diseases that
are rooted in perturbations of protein stability, protein folds
and protein assemblies. The case of serpinopathies, reminis-
cent of amyloid related disorders but based on entirely dif-
ferent mechanistic models, provides an open example of such
a trend. NS shares most of the serpin family structural and
functional properties, including the inhibition mechanism
against a serine protease (tPA) and the manifestation of dif-
ferent molecular monomeric/polymeric forms. The ensemble
of genetic, cellular, molecular, biophysical and structural
studies presented here depicts the complexity of the pro-
cesses that must be understood and controlled to provide
clues for human therapies against the growing category of
protein misfolding/aggregation diseases.
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